blog

Ergothioneine (EGT) delivers comprehensive skin benefits via antioxidant, anti-inflammatory, photoprotective, and collagen-stimulating actions.

Ergothioneine, hailed as the “Longevity Vitamin,” targets mitochondria via OCTN1 transporters, offering unparalleled antioxidant, anti-fatigue, and anti-aging effects. Tianming Pharma details L-form purity (>99.99%), glutathione synergy, and science-backed alternatives like NMN/PQQ.

Orforglipron’s non-peptide scaffold (23 atoms) enables oral GLP-1 therapy via acid-stable triazole core, (R)-chlorophenyl chiral targeting, and pyridine N-oxide H-bonding. Tianming Pharma provides key intermediates for scalable synthesis.

We have made a major breakthrough in the production of orforglipron intermediates. We now offer a range of orforglipron intermediates with detailed information. Please contact us for more information to meet your pharmaceutical needs.

This article examines six pivotal trends reshaping the 2025 pharma intermediates sector: Asia’s manufacturing evolution, continuous production adoption, AI-driven R&D acceleration, ESG compliance pressures, nearshoring strategies, and biomanufacturing breakthroughs.

This article explores Idebenone, a supercharged antioxidant surpassing Vitamins C/E. It details its molecular advantages, anti-aging efficacy, and practical usage tips. Learn to select high-purity Idebenone products.

As a leading API/intermediate manufacturer, we showcase advanced synthesis tech and regulatory-ready solutions at CPHI 2025. Booth No.: W2G30

Expert analysis of API synthesis complexities: route selection trade-offs, scale-up challenges, impurity control tactics, and green chemistry innovations. Includes industrial case studies on yield optimization and troubleshooting.

This guide reveals why your Pharmaceutical Ingredient List is vital for compliance and innovation. Learn sourcing strategies, quality benchmarks, and 2024 API trend（Attached API list）

Analyzes molecular, manufacturing, and clinical distinctions between orforglipron and GLP-1 Receptor Agonists. Covers stability, scalability, and sourcing strategies for metabolic drug developers.